India to consider clutch of foreign pharma acquisition plans on January 20
This article was originally published in Scrip
Executive Summary
A clutch of investment proposals, including domestic acquisitions by the US firms Akorn and Par Pharmaceutical, are expected to come up for approval by India's Foreign Investment Promotion Board (FIPB) later this week.